Caring for patients with cancer in the COVID-19 era.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
04
04
2020
accepted:
06
04
2020
entrez:
15
5
2020
pubmed:
15
5
2020
medline:
19
5
2020
Statut:
ppublish
Résumé
The current COVID-19 pandemic challenges oncologists to profoundly re-organize oncological care in order to dramatically reduce hospital visits and admissions and therapy-induced immune-related complications without compromising cancer outcomes. Since COVID-19 is a novel disease, guidance by scientific evidence is often unavailable, and impactful decisions are inevitably made on the basis of expert opinions. Here we report how the seven comprehensive cancer centers of Cancer Core Europe have organized their healthcare systems at an unprecedented scale and pace to make their operations 'pandemic proof'. We identify and discuss many commonalities, but also important local differences, and pinpoint critical research priorities to enable evidence-based remodeling of cancer care during the COVID-19 pandemic. Also, we discuss how the current situation offers a unique window of opportunity for assessing the effects of de-escalating anticancer regimens, which may fast-forward the development of more-refined and less-toxic treatments. By sharing our joint experiences, we offer a roadmap for proceeding and aim to mobilize the global research community to generate the data that are critically needed to offer the best possible care to patients.
Identifiants
pubmed: 32405058
doi: 10.1038/s41591-020-0874-8
pii: 10.1038/s41591-020-0874-8
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
665-671Subventions
Organisme : Department of Health
ID : NIHR300024
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : AssociatedDataset
Références
Emanuel, E.J. et al. Fair allocation of scarce medical resources in the time of Covid-19. N. Engl. J. Med. (2020).
Calvo, F. et al. Cancer Core Europe: a European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century. Eur. J. Cancer 103, 155–159 (2018).
doi: 10.1016/j.ejca.2018.08.023
Eggermont, A. M. et al. Cancer Core Europe: a consortium to address the cancer care-cancer research continuum challenge. Eur. J. Cancer 50, 2745–2746 (2014).
doi: 10.1016/j.ejca.2014.07.025
Eggermont, A. M. M. et al. Cancer Core Europe: a translational research infrastructure for a European mission on cancer. Mol. Oncol. 13, 521–527 (2019).
doi: 10.1002/1878-0261.12447
Coles, C. E. et al. International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic. Clin. Oncol. 32, 279–281 (2020).
doi: 10.1016/j.clon.2020.03.006
Kunisaki, K. M. & Janoff, E. N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis. 9, 493–504 (2009).
doi: 10.1016/S1473-3099(09)70175-6
Bitterman, R. et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst. Rev. 2, CD008983 (2018).
pubmed: 29388675
Liang, W. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 21, 335–337 (2020).
doi: 10.1016/S1470-2045(20)30096-6
Wang, H. & Zhang, L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 21, e181 (2020).
doi: 10.1016/S1470-2045(20)30149-2
Xia, Y., Jin, R., Zhao, J., Li, W. & Shen, H. Risk of COVID-19 for patients with cancer. Lancet Oncol. 21, e180 (2020).
doi: 10.1016/S1470-2045(20)30150-9
Zhang, L. et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann. Oncol. https://doi.org/10.1016/j.annonc.2020.03.296 (2020).
Zhou, Y. et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci. Rev. (2020).
Yang, Y. et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv https://doi.org/10.1101/2020.02.11.20021493 (2020).
Lefevre, J. H. et al. Effect of interval (7 or 11 weeks) Between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J. Clin. Oncol. 34, 3773–3780 (2016).
doi: 10.1200/JCO.2016.67.6049
National Health Service (NHS) England. Clinical guide for the management of non-coronavirus patients requiring acute treatment: Cancer (Publications approval reference: 001559). https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/specialty-guide-acute-treatment-cancer-23-march-2020.pdf (2020).
Walker, P. et al. The global impact of COVID-19 and strategies for mitigation and suppression. Imperial College London https://doi.org/10.25561/77735 (2020).